137 related articles for article (PubMed ID: 17553925)
1. Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Kaul P
Eur Heart J; 2007 Jun; 28(12):1405-6. PubMed ID: 17553925
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Hilleman DE; Wurdeman RL; Lenz TL
Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
[TBL] [Abstract][Full Text] [Related]
5. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
7. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
[TBL] [Abstract][Full Text] [Related]
8. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
Brun J; Ohlsson-Onerud A; Sörensen N
Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
[No Abstract] [Full Text] [Related]
9. Is initiation of atorvastatin for employees a good buy for employers?
Culler SD; Weintraub WS
Mayo Clin Proc; 2009 Dec; 84(12):1059-61. PubMed ID: 19955241
[No Abstract] [Full Text] [Related]
10. High-dose statins and the IDEAL study.
Mann SJ
JAMA; 2006 Jun; 295(21):2477-8; author reply 2478-9. PubMed ID: 16757715
[No Abstract] [Full Text] [Related]
11. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Schwartz GG; Ganz P; Waters D; Arikian S
Am J Cardiol; 2003 Nov; 92(9):1109-12. PubMed ID: 14583367
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Wagner M; Lindgren P; Merikle E; Goetghebeur M; Jönsson B
Can J Cardiol; 2009 Nov; 25(11):e362-9. PubMed ID: 19898698
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
[TBL] [Abstract][Full Text] [Related]
15. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
16. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Weizel A; Sawicki PT
MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
[No Abstract] [Full Text] [Related]
17. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
Mark DB; Knight JD; Cowper PA; Davidson-Ray L; Anstrom KJ
Am Heart J; 2008 Oct; 156(4):698-705. PubMed ID: 18926150
[TBL] [Abstract][Full Text] [Related]
18. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
Lachaine J; Merikle E; Tarride JE; Montpetit M; Rinfret S
Clin Ther; 2007 Mar; 29(3):519-28. PubMed ID: 17577472
[TBL] [Abstract][Full Text] [Related]
19. Statin wars: efficacy vs. cost.
Wierzbicki AS
Int J Clin Pract; 2011 Feb; 65(2):108-11. PubMed ID: 21235691
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
